

In this Issue ...

- [From the President](#)
- [ISPOR 7th Asia Pacific Conference](#)
- [An Afternoon with Mike](#)
- [Quality of Life Workshop](#)
- [2017 ISPOR-AC Events](#)
- [Corporate Membership](#)
- [Student Membership](#)
- [Conference Calendar](#)



[From the President](#)

*Written by Stephen Goodall
President, ISPOR Australian Chapter*

As we near the end of another successful year for the ISPOR-Australia Chapter, I would like to reflect on the activities of 2016. Our first workshop of the year “Contemporary Economic Modelling” was an overwhelming success with over 90 attendees. This workshop provided an opportunity for researchers to present their economic models and receive expert feedback.

In August, a joint collaboration between ISPOR AU, Quality of Life office (USyd) and Cancer Research Economic Support Team (UTS) hosted the “Quality of life and utility measures in cancer research” workshop. I would particularly like to thank Prof. Madeleine King, Prof. Rosalie Viney, Brendan Mulhern and Richard De Abreu Lourenco for delivering this educational workshop.

In September, ISPOR AU interviewed Prof Mike Drummond (Past President of ISPOR) regarding the recent developments in HTA globally. Thank you to Prof. Paul Scuffham for arranging this event and Pfizer for hosting the event. Finally, I would like to thank our New Zealand colleagues, in particular Chris

Cariswell, for allowing ISPOR AC members to view the excellent webinar with Prof. Jaime Caro "ISPOR NZ Webinar: An Introduction to Discretely Integrated Condition Event Simulation". Jaime is a global expert and pioneer in the economic modelling of drug therapies.

As usual, Australia was well represented at the 2016 ISPOR Asia-Pacific conference (Singapore). During the meeting George Papadopoulos and I met with Nancy Berg (ISPOR CEO & Executive Director) regarding the possibility of Australia hosting the 2020 ISPOR Asia-Pacific conference. Our proposal was well received and we expect an announcement early in 2017. Please see Bill's article below for more details regarding the ISPOR Asia Pacific conference.

I would like to thank you for your support in 2016, and look forward to seeing you at our next workshop in March 2017.

ISPOR-AC would like to wish its members a joyous holiday season and a most prosperous and healthy New Year.

Stephen Goodall



ISPOR 7th Asia-Pacific Conference

Written by Bill Montgomery

The ISPOR Asia-Pacific conference has grown in size and impact since the first meeting in Kobe, Japan in 2004 that had 250 delegates. The 2016 meeting in Singapore had 1,283 delegates attending from 53 countries, including 75 people from Australia. In that time we have seen the introduction of HTA systems in many countries across the Asia-Pacific region and an increase in the sophistication of the research presented and in the complexity of the policy issues tackled.


Key themes of the conference included the evolution of health technology assessment (HTA) within Asia, the use of real world data (big data) as a powerful research tool to inform decision making & policy development, and an update on the progress of achieving universal health coverage within the ASEAN region. The conference was well attended by members of the Australian Chapter who contributed to a number of issue panels in partnership with well known academics and HTA experts from Australia. Topics included, the current experience on handling uncertainty in economic modelling, the evolution of risk management schemes in Australia and issues with using clinical trials for both drug registration and

reimbursement purposes.

Highlights:

- HTA in the AP region. Takashi Fukuda, from Japan provided an up-date on the progress of the implementation of a HTA system for pharmaceuticals in Japan, beginning with details of a pilot program evaluating seven drugs and six medical devices in April 2016. As Japan is the second largest market for pharmaceuticals globally, and a country with a long history of providing universal health coverage there was considerable interest in the progress of this new system.
- Adapting pharmacoeconomic data from other countries. Michael Drummond lead a workshop on adapting pharmacoeconomic data from overseas for use in decision making in middle income countries within the Asia-Pacific region, with co-leads presenting their experience from Korea, Taiwan and Thailand.
- Big data. Libby Roughead moderated a forum on Big Data in the Asia-Pacific, where the experiences and lessons learned from Australia, Japan, Singapore, Korea and Taiwan were shared by researchers working in each of these countries.

Follow the link below to access the released presentations from the conference <http://www.ispor.org/Event/ReleasedPresentations/2016Singapore>



An Afternoon with Mike


Written by Colman Taylor

The ISPOR Australia Chapter was pleased to host Professor Mike Drummond in September at the Pfizer headquarters in Sydney. Mike is Professor of Health Economics and a former Director of the Centre for Health Economics at the University of York. He is also a past president of ISPOR and is currently Co-Editor-in-Chief of Value in Health. Most ISPOR members are very familiar with Mike's academic work, with many in the audience owning a well-worn copy of his text book.

Mike's talk focused on an overview of international health technology assessment (HTA) methods – including where we stand today and where we are headed. This topic was particularly timely given the audience was still digesting the recent release of v5.0 of the PBAC guidelines in Australia.

During an international overview of HTA guidelines Mike highlighted several discrepancies between countries including how a comparator is defined and what perspective should be adopted in an evaluation. Regarding value assessment frameworks, Mike spoke to the difference between 'QALY lovers', including countries such as Australia and the UK, and 'QALY sceptics', including countries such as Germany and the US. Recent developments in HTA in the US were of particular interest, as momentum has continued to develop despite legislation specifically prohibiting the use of QALYs and thresholds to determine coverage.

In terms of future developments, Mike covered discrete choice methods and multi-criteria decision analysis (MCDA) and their application in HTA frameworks. He also spoke to innovative financing models for pharmaceuticals including performance based risk-share and leasing technologies for long term cures.



Quality of Life Workshop

Written by Stephen Goodall

In August, ISPOR AU, Quality of Life (USyD) and Cancer Research Economic Support Team (UTS) jointly hosted the "Quality of life and utility measures in cancer research" workshop. This workshop was developed in collaboration with Prof. Madeleine King, Prof. Rosalie Viney, Brendan Mulhern and Richard De Abreu Lourenco, leading experts in this area of research.

During the workshop participants discussed the pros and cons of using patient-reported outcomes and health-related QoL, the benefits of generic measures and cancer specific outcome measures, such as the

QLQ-C30 and FACT-G. There was also an overview of the commonly used multi-attribute utility instruments (MAUIs) and the various preference elicitation methods, such as time-trade off, standard gamble and discrete choice experiments.

The workshop concluded with an introduction to the development and valuation of a cancer-specific MAUI (QLU-C10D), which was developed by the Multi-Attribute Utility in Cancer (MAUCa) Consortium from the EORTC QLQ-C30. Participants were also provided guidance on how to appropriately choose HRQOL and utility measures for a clinical study.

The workshop was very interactive, with participants completing QoL questionnaires and developing scoring algorithms. The industry perspective was excellently provided by ISPOR AU President-Elect Hansoo Kim (BMS).



[2017 ISPOR-AC Calendar of Events](#)

Keep an eye on the website for updates and when registrations open www.isporac.org

21 March 2017

Preferences and Willingness to Pay Workshop

ISPOR Australian Chapter Annual General Meeting

Aerial Function Centre, UTS, Sydney

August 2017

Quality of Life Workshop

Deakin's Melbourne City Centre, Melbourne

November 2017

Workshop theme TBA

Aerial Function Centre, UTS, Sydney

ISPOR International Events in 2017[ISPOR 22nd Annual International Meeting](#)

Dates: 20-24 May 2017

Location: Boston, MA USA

[ISPOR 6th Latin America Conference](#)

Dates: 15-17 September 2017

Location: Sao Paulo, Brazil

[ISPOR 20th Annual European Congress](#)

Dates: 4-8 November 2017

Location: Glasgow Scotland

**Become a
Member**

[Corporate Membership](#)

Corporate Membership with ISPOR-AC offers a premium level of membership with unparalleled personalised service to meet your business needs. Membership at this level is intended to be all encompassing, offering all the benefits of General Membership plus more. We have a package to suit your company.

[Student Membership](#)

Students can now join ISPOR-AC for FREE. You will need to join with your university student email address. The student membership lasts the length of your degree.

The ISPOR-AC Executive Committee are also searching for a student committee member. If you are interested please head to the [Committee](#) page on the website for more information

To join head to the [Memberships](#) page on the ISPOR-AC website

[Conference Calendar](#)

[HTAi 2017 Annual Meeting](#), 17 - 21 June 2017, Rome, Italy

[iHEA 2017 Congress](#), 7-11, 2017, Boston, Massachusetts, USA

[ARCS Annual Conference](#) 22 - 24 August 2017, Australian Turf Club, Randwick, Sydney

ISPOR Australia Chapter acknowledges its Corporate Members

- Centre for Health Economics Research and Evaluation, University of Technology Sydney
- Bristol-Myers Squibb
- Astra-Zeneca
- Bayer Australia



Twitter



LinkedIn



Email



Website

Copyright © 2016 ISPOR Australia Chapter, All rights reserved.

[unsubscribe from this list](#) [update subscription preferences](#)

MailChimp